21.45
0.19%
-0.04
Fusion Pharmaceuticals Inc stock is currently priced at $21.45, with a 24-hour trading volume of 468.49K.
It has seen a -0.19% decreased in the last 24 hours and a +0.52% rose in the past month.
The chart indicates a potential bearish trend, as the stock is below the $21.49 pivot point. If it approaches the $21.42 support level, significant changes may occur.
Previous Close:
$21.49
Open:
$21.5
24h Volume:
468.49K
Market Cap:
$1.82B
Revenue:
$2.21M
Net Income/Loss:
$-94.90M
P/E Ratio:
-11.11
EPS:
-1.93
Net Cash Flow:
$-85.69M
1W Performance:
+0.14%
1M Performance:
+0.52%
6M Performance:
+369.37%
1Y Performance:
+424.45%
Fusion Pharmaceuticals Inc Stock (FUSN) Company Profile
Name
Fusion Pharmaceuticals Inc
Sector
Industry
Phone
289 799 0891
Address
270 Longwood Road South, Hamilton
Fusion Pharmaceuticals Inc Stock (FUSN) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Dec-27-23 | Upgrade | Raymond James | Outperform → Strong Buy |
Sep-29-23 | Initiated | Oppenheimer | Outperform |
Jun-23-23 | Initiated | Raymond James | Outperform |
Dec-01-22 | Resumed | B. Riley Securities | Buy |
Nov-30-22 | Initiated | SVB Leerink | Outperform |
Sep-16-22 | Initiated | Truist | Buy |
Jul-06-22 | Initiated | William Blair | Outperform |
Oct-19-21 | Resumed | Morgan Stanley | Overweight |
Aug-26-21 | Initiated | B. Riley Securities | Buy |
Jul-21-20 | Initiated | Cowen | Outperform |
Jul-21-20 | Initiated | Jefferies | Buy |
Jul-21-20 | Initiated | Wedbush | Outperform |
View All
Fusion Pharmaceuticals Inc Stock (FUSN) Latest News
Fusion Pharmaceuticals Inc. (FUSN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Zacks Investment Research
Fusion Pharmaceuticals Inc. (FUSN) Ascends But Remains Behind Market: Some Facts to Note
Zacks Investment Research
AstraZeneca (AZN) to Report Q1 Earnings: Here's What to Expect
Zacks Investment Research
Fusion Pharmaceuticals Inc. (FUSN) Stock Moves -0.09%: What You Should Know
Zacks Investment Research
Fusion Pharmaceuticals Inc. (FUSN) Flat As Market Gains: What You Should Know
Zacks Investment Research
Novo Nordisk (NVO) to Buy Cardior to Boost Heart Disease Pipeline
Zacks Investment Research
Fusion Pharmaceuticals Inc Stock (FUSN) Financials Data
Fusion Pharmaceuticals Inc (FUSN) Revenue 2024
FUSN reported a revenue (TTM) of $2.21 million for the quarter ending September 30, 2023, a +15.30% rise year-over-year.
Fusion Pharmaceuticals Inc (FUSN) Net Income 2024
FUSN net income (TTM) was -$94.90 million for the quarter ending December 31, 2023, a -8.32% decrease year-over-year.
Fusion Pharmaceuticals Inc (FUSN) Cash Flow 2024
FUSN recorded a free cash flow (TTM) of -$85.69 million for the quarter ending December 31, 2023, a -13.62% decrease year-over-year.
Fusion Pharmaceuticals Inc (FUSN) Earnings per Share 2024
FUSN earnings per share (TTM) was -$1.47 for the quarter ending December 31, 2023, a +26.50% growth year-over-year.
About Fusion Pharmaceuticals Inc
Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines. The company has developed Targeted Alpha Therapies platform together with its proprietary Fast-Clear linker technology to enable us to connect alpha particle emitting isotopes to antibodies and other targeting molecules in order to selectively deliver the alpha particle payloads to tumors. Its lead product candidate is FPI-1434 that is in Phase 1 clinical trials as a monotherapy in patients with solid tumors expressing insulin-like growth factor 1 receptor. The company is also conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, it is progressing its earlier-stage product candidate, FPI-1966 into clinical development for the treatment of head and neck, and bladder cancers expressing fibroblast growth factor receptor. The company was founded in 2014 and is headquartered in Hamilton, Canada.
Cap:
|
Volume (24h):